Literature DB >> 6258825

125I radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method.

S M Owens, A J McBay, H M Reisner, M Perez-Reyes.   

Abstract

In this sensitive and specific radioimmunoassay for delta-9-tetrahydrocannabinol, an iodinated tracer with high specific activity and a solid-phase separation are used. Within-run coefficients of variation for 5.0 and 30.0 microgram/L concentrations were 7.8 and 4.2% for plasma and 14 and 10.6% for hemolyzed blood specimens, respectively. Day-to-day coefficients of variations ranged from 7.3 to 13.6% (for 7.6 to 33.0 microgram/L concentrations) for plasma and 13.4 to 18.1% (3.0 to 52.1 microgram/L) for hemolyzed blood specimens. Data for time after start of smoking of a standard THC-containing cigarette vs the concentration of delta-9-tetrahydrocannabinol in the plasma were similar to those obtained by others. Positive plasma specimens from the smoking study were analyzed by gas chromatography-mass spectrometry and by our radioimmunoassay. Nonparametric statistical comparison and linear regression (r2 = 0.972) showed that results by the two methods of analysis correlate well. The sensitivity of the assay was at least 0.3 microgram/L for plasma, 1.1 microgram/L for hemolyzed blood.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6258825

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

2.  Relationships between several pharmacokinetic parameters and psychometric indices of subjective effects of delta 9-tetrahydrocannabinol in man.

Authors:  L L Miller; D M Cocchetto; M Perez-Reyes
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Kinetic study of smoking marijuana.

Authors:  G Barnett; C W Chiang; M Perez-Reyes; S M Owens
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

4.  Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Authors:  Erin L Karschner; Madeleine J Swortwood; Jussi Hirvonen; Robert S Goodwin; Wendy M Bosker; Johannes G Ramaekers; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-06-11       Impact factor: 3.345

5.  Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Authors:  Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

6.  Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man.

Authors:  D M Cocchetto; S M Owens; M Perez-Reyes; S DiGuiseppi; L L Miller
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 7.  Harmful Effects of Smoking Cannabis: A Cerebrovascular and Neurological Perspective.

Authors:  Sabrina Rahman Archie; Luca Cucullo
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

8.  Chemistry, metabolism, and toxicology of cannabis: clinical implications.

Authors:  Priyamvada Sharma; Pratima Murthy; M M Srinivas Bharath
Journal:  Iran J Psychiatry       Date:  2012

9.  The Relationship Between Plasma Tetrahydrocannabinol Levels and Intraocular Pressure in Healthy Adult Subjects.

Authors:  Sameh Mosaed; Andrew K Smith; John H K Liu; Donald S Minckler; Robert L Fitzgerald; David Grelotti; Emily Sones; Robert N Weinreb; Thomas D Marcotte
Journal:  Front Med (Lausanne)       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.